DarioHealth Corp. (NASDAQ:DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition digital therapeutics platform.
Company profile
Ticker
DRIO
Exchange
Website
CEO
Erez Raphael
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LabStyle Innovations Corp.
SEC CIK
Corporate docs
Subsidiaries
Labstyle Innovation Ltd. • PsyInnovations Inc. • DarioHealth India Services Pvt. Ltd. • Twill, Inc. ...
DRIO stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
5 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Other Events
1 Mar 24
D
$22.42 mm in equity / securities to be acquired, sold $22.42 mm, 119 investors
29 Feb 24
8-K
Regulation FD Disclosure
22 Feb 24
S-8
Registration of securities for employees
21 Feb 24
8-K
Entry into a Material Definitive Agreement
21 Feb 24
S-8
Registration of securities for employees
19 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
11 Dec 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
Transcripts
DRIO
Earnings call transcript
2023 Q3
2 Nov 23
DRIO
Earnings call transcript
2023 Q2
10 Aug 23
DRIO
Earnings call transcript
2023 Q1
11 May 23
DRIO
Earnings call transcript
2022 Q4
9 Mar 23
DRIO
Earnings call transcript
2022 Q3
15 Nov 22
DRIO
Earnings call transcript
2022 Q2
15 Aug 22
DRIO
Earnings call transcript
2022 Q1
12 May 22
DRIO
Earnings call transcript
2021 Q4
22 Mar 22
DRIO
Earnings call transcript
2021 Q3
16 Nov 21
DRIO
Earnings call transcript
2021 Q2
16 Aug 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 44.22 mm | 44.22 mm | 44.22 mm | 44.22 mm | 44.22 mm | 44.22 mm |
Cash burn (monthly) | 2.91 mm | 1.08 mm | 5.24 mm | 4.81 mm | 2.88 mm | 2.58 mm |
Cash used (since last report) | 19.25 mm | 7.16 mm | 34.71 mm | 31.86 mm | 19.08 mm | 17.09 mm |
Cash remaining | 24.98 mm | 37.06 mm | 9.51 mm | 12.36 mm | 25.14 mm | 27.13 mm |
Runway (months of cash) | 8.6 | 34.2 | 1.8 | 2.6 | 8.7 | 10.5 |
Institutional ownership, Q3 2023
37.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 44 |
Opened positions | 3 |
Closed positions | 6 |
Increased positions | 16 |
Reduced positions | 12 |
13F shares | Current |
---|---|
Total value | 29.70 bn |
Total shares | 11.12 mm |
Total puts | 3.90 k |
Total calls | 6.70 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Nantahala Capital Management | 2.41 mm | $7.92 bn |
PXGPE Phoenix | 1.34 mm | $4.40 bn |
Appian Way Asset Management | 1.29 mm | $4.23 bn |
Y.D. More Investments | 1.29 mm | $4.23 bn |
Walleye Capital | 1.21 mm | $3.97 bn |
Kershner Trading Americas,LLC | 1.05 mm | $0.00 |
Clal Insurance Enterprises | 936.67 k | $3.07 mm |
Vanguard | 302.01 k | $990.59 mm |
Geode Capital Management | 270.57 k | $887.71 mm |
Shay Capital | 150.00 k | $492.00 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Mar 24 | Ben-David Zvi | Common Stock | Grant | Acquire A | No | No | 0 | 400,000 | 0.00 | 746,035 |
6 Mar 24 | Shaked Yoav | Common Stock | Grant | Acquire A | No | No | 0 | 90,000 | 0.00 | 256,193 |
6 Mar 24 | Richard Allan Anderson | Stock Option Common Stock | Grant | Acquire A | No | No | 1.68 | 320,000 | 537.60 k | 320,000 |
6 Mar 24 | Richard Allan Anderson | Stock Option Common Stock | Grant | Acquire A | No | No | 1.68 | 750,000 | 1.26 mm | 750,000 |
6 Mar 24 | Jon H. Kaplan | Common Stock | Grant | Acquire A | No | No | 0 | 70,000 | 0.00 | 70,000 |
6 Mar 24 | Karah Hila | Common Stock | Grant | Acquire A | No | No | 0 | 70,000 | 0.00 | 219,290 |
News
Dario Publishes Two Peer-Reviewed Studies Demonstrating Impact Of Digital Behavioral Health
10 Apr 24
Two National Employers Select Dario's Integrated Chronic Condition Solution To Improve Employee Health
2 Apr 24
Stifel Maintains Buy on DarioHealth, Maintains $4 Price Target
1 Apr 24
DarioHealth Q4 EPS $(0.41) Beats $(0.54) Estimate
28 Mar 24
DarioHealth Q4 Sales $3.62M Beat $3.57M Estimate
28 Mar 24
Press releases
Dario Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral Health
10 Apr 24
Two National Employers Select Dario's Integrated Chronic Condition Solution to Improve Employee Health
2 Apr 24
DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results
28 Mar 24
DARIOHEALTH TO REPORT FOURTH QUARTER 2023 RESULTS ON THURSDAY, MARCH 28TH
21 Mar 24
New Research from Dario Demonstrates Ability to Deliver Improved Health Outcomes with Integrated Solution for Members Managing Weight and Blood Glucose with or without GLP-1 Medications
12 Mar 24